医学
放射科
尿路上皮癌
临床试验
梅德林
肿瘤科
临床研究阶段
相(物质)
转移
肿瘤分期
肾癌
内科学
外科
膀胱癌
作者
Ekaterina Laukhtina,Dina Muin,Clemens P. Spielvogel,Lukas Nics,Agata Suleja,Johanna Krauter,Eva Stöckel,Irene Hübner-Resch,Anka Mihajlovic,Stefan Schmitl,Elisabeth Kretschmer‐Chott,Bernhard Englinger,Sazan Rasul,Pascal Baltzer,Marcus Hacker,Shahrokh F. Shariat
标识
DOI:10.1016/j.eururo.2026.10.018
摘要
Enfortumab vedotin (EV), an anti–nectin-4 antibody-drug conjugate, alone and with pembrolizumab (EV plus pembrolizumab [EV/P]), has transformed the treatment of locally advanced/metastatic urothelial carcinoma (la/mUC), yet remains biomarker agnostic. We prospectively evaluated [ 68 Ga]Ga-DOTA-N188 PET/CT ([ 68 Ga]-N188 PET/CT) as a whole-body alternative for nectin-4 imaging, with [ 18 F]-FDG PET/CT as an active comparator and conventional computed tomography as the reference standard for staging la/mUC in 25 patients planned for EV/P. [ 18 F]-FDG PET/CT showed a higher maximum standardized uptake value and tumor-to-background ratio than [ 68 Ga]-N188 PET/CT across most lesion types (primary tumor, visceral, and osseous), except for lymph nodes. The overall tracer correlation was weak (Spearman r = 0.196), strongest in lymph nodes ( r = 0.657), and absent in primary tumors and bone lesions. For primary tumor detection, [ 68 Ga]-N188 PET/CT had higher specificity (86% vs 57%) and positive predictive value (92% vs 83%) than FDG, which had higher sensitivity (88% vs 67%). Nodal staging performance was similar in the tracers. For distant metastases, both achieved 100% sensitivity and negative predictive value, with [ 68 Ga]-N188 PET/CT showing marginally higher specificity. [ 68 Ga]-N188 PET/CT is feasible for whole-body nectin-4 assessment in la/mUC and supports a distinct biodistribution from FDG, suggesting complementary rather than interchangeable roles. Further prospective evaluation with treatment-outcome correlation is warranted before its use as a biomarker to guide EV-based therapy selection.
科研通智能强力驱动
Strongly Powered by AbleSci AI